BLTE vs. PRTA, GYRE, IRWD, SYRE, PCRX, LGND, MIRM, COLL, GMTX, and MNKD
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Prothena (PRTA), Gyre Therapeutics (GYRE), Ironwood Pharmaceuticals (IRWD), Spyre Therapeutics (SYRE), Pacira BioSciences (PCRX), Ligand Pharmaceuticals (LGND), Mirum Pharmaceuticals (MIRM), Collegium Pharmaceutical (COLL), Gemini Therapeutics (GMTX), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.
Prothena (NASDAQ:PRTA) and Belite Bio (NASDAQ:BLTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.
Belite Bio has lower revenue, but higher earnings than Prothena. Belite Bio is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Prothena has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.52, suggesting that its stock price is 252% less volatile than the S&P 500.
In the previous week, Prothena had 1 more articles in the media than Belite Bio. MarketBeat recorded 7 mentions for Prothena and 6 mentions for Belite Bio. Prothena's average media sentiment score of 0.30 beat Belite Bio's score of -0.17 indicating that Belite Bio is being referred to more favorably in the news media.
Prothena presently has a consensus target price of $68.14, suggesting a potential upside of 208.34%. Belite Bio has a consensus target price of $44.83, suggesting a potential upside of 5.24%. Given Belite Bio's higher probable upside, equities analysts plainly believe Prothena is more favorable than Belite Bio.
Belite Bio has a net margin of 0.00% compared to Belite Bio's net margin of -160.91%. Belite Bio's return on equity of -24.84% beat Prothena's return on equity.
Prothena received 578 more outperform votes than Belite Bio when rated by MarketBeat users. However, 95.24% of users gave Belite Bio an outperform vote while only 70.60% of users gave Prothena an outperform vote.
97.1% of Prothena shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 28.1% of Prothena shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Prothena beats Belite Bio on 10 of the 17 factors compared between the two stocks.
Get Belite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belite Bio Competitors List
Related Companies and Tools
